Showing results (211-220 of 327) with videos related to
Sort By:
Pageof 33
The EMBO Journal|February 25, 2021
Calcium flux control by Pacs1-Wdr37 promotes lymphocyte quiescence and lymphoproliferative diseasesEvan Nair-Gill, Massimo Bonora, Xue Zhong, et al.Cell Host & Microbe|March 16, 2011
Hypomorphic mutation in the site-1 protease Mbtps1 endows resistance to persistent viral infection in a cell-specific mannerDaniel L Popkin, John R Teijaro, Brian M Sullivan, et al.Biorxiv : the Preprint Server for Biology|March 27, 2026
PPa1 insufficiency drives lysosomal storage disease and inflammatory macrophage expansion in the bone marrowMagdalena Grzemska, Luming Chen, Jamie Russell, et al.Immunity|June 20, 2006
Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathwayEdith Janssen, Koichi Tabeta, Michael J Barnes, et al.Journal of Medicinal Chemistry|June 29, 2022
Next-Generation Diprovocims with Potent Human and Murine TLR1/TLR2 Agonist Activity That Activate the Innate and Adaptive Immune ResponseMing-Hsiu Yang, Jamie L Russell, Yuto Mifune, et al.Disease Models & Mechanisms|May 3, 2022
Modulation of autoimmune diabetes by N-ethyl-N-nitrosourea- induced mutations in non-obese diabetic miceLucienne Chatenoud, Cindy Marquet, Fabrice Valette, et al.Nature Immunology|May 17, 2005
CD14 is required for MyD88-independent LPS signalingZhengfan Jiang, Philippe Georgel, Xin Du, et al.Proceedings of the National Academy of Sciences of the United States of America|July 22, 2021
Sulfatides are endogenous ligands for the TLR4-MD-2 complexLijing Su, Muhammad Athamna, Ying Wang, et al.Journal of the American Chemical Society|October 2, 2018
Diprovocims: A New and Exceptionally Potent Class of Toll-like Receptor AgonistsMatthew D Morin, Ying Wang, Brian T Jones, et al.Nature Communications|July 16, 2022
Loss of immunity-related GTPase GM4951 leads to nonalcoholic fatty liver disease without obesityZhao Zhang, Yu Xun, Shunxing Rong, et al.Pageof 33